New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
08:17 EDTMRTXMirati Therapeutics price target raised to $27 from $20 at Brean Capital
Brean Capital raised its price target on Mirati Therapeutics as the company continues to move its pipeline forward, positive trials updates, and expectations for upfront payments and royalties from potential partnerships. Shares are Buy rated.
News For MRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 10, 2014
08:09 EDTMRTXMirati Therapeutics reports Q3 EPS (72c), consensus (76c)

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use